ATE230435T1 - In vitro aktivierung cytotoxischer t-zellen - Google Patents

In vitro aktivierung cytotoxischer t-zellen

Info

Publication number
ATE230435T1
ATE230435T1 AT93906141T AT93906141T ATE230435T1 AT E230435 T1 ATE230435 T1 AT E230435T1 AT 93906141 T AT93906141 T AT 93906141T AT 93906141 T AT93906141 T AT 93906141T AT E230435 T1 ATE230435 T1 AT E230435T1
Authority
AT
Austria
Prior art keywords
cytotoxic
cells
autoimmune
class
relates
Prior art date
Application number
AT93906141T
Other languages
English (en)
Inventor
Per A Peterson
Michael Jackson
Pierre Langlade-Demoyen
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE230435T1 publication Critical patent/ATE230435T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0601Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5156Animal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48Blood cells, e.g. leukemia or lymphoma
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/75Vector systems having a special element relevant for transcription from invertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
AT93906141T 1992-02-19 1993-02-18 In vitro aktivierung cytotoxischer t-zellen ATE230435T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/841,662 US5314813A (en) 1992-02-19 1992-02-19 Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
PCT/US1993/001557 WO1993017095A1 (en) 1992-02-19 1993-02-18 In vitro activation of cytotoxic t cells

Publications (1)

Publication Number Publication Date
ATE230435T1 true ATE230435T1 (de) 2003-01-15

Family

ID=25285417

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02014141T ATE338815T1 (de) 1992-02-19 1993-02-18 In vitro aktivierung von cytotoxischen t zellen
AT93906141T ATE230435T1 (de) 1992-02-19 1993-02-18 In vitro aktivierung cytotoxischer t-zellen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02014141T ATE338815T1 (de) 1992-02-19 1993-02-18 In vitro aktivierung von cytotoxischen t zellen

Country Status (10)

Country Link
US (3) US5314813A (de)
EP (2) EP1249490B1 (de)
JP (2) JP3739786B2 (de)
AT (2) ATE338815T1 (de)
AU (1) AU3728193A (de)
DE (2) DE69332606T2 (de)
DK (2) DK1249490T3 (de)
ES (2) ES2272611T3 (de)
PT (1) PT1249490E (de)
WO (1) WO1993017095A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5583031A (en) * 1992-02-06 1996-12-10 President And Fellows Of Harvard College Empty major histocompatibility class II heterodimers
CA2069541C (en) * 1992-05-26 2005-02-01 Cornelis J. M. Melief Induction of an antigen-specific t-lymphocyte response
EP1704868A1 (de) * 1992-08-07 2006-09-27 Pharmexa Inc. HLA Bindepeptide und ihre Verwendungen
US5571669A (en) * 1993-01-14 1996-11-05 The University Of Pennsylvania Transcription and nucleic acid sequence determination with short primer DNA/RNA molecules and RNA polymerase
AU7478394A (en) * 1993-08-06 1995-02-28 Cytel Corporation Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
FR2710536B1 (fr) * 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
US6090587A (en) * 1993-10-25 2000-07-18 Corixa Corporation Prokaryotic expression of MHC proteins
FR2722207B1 (fr) * 1994-07-07 1996-09-27 Inst Nat Sante Rech Med Methode pour generer une population de cellules presentant a leur surface une forte densite d'un pepride exogene specifique associe azx molecules du cmh; population de cellules
US5674681A (en) 1994-12-06 1997-10-07 Rothenberg; Barry E. Methods to identify hemochromatosis
ES2201177T3 (es) * 1995-03-08 2004-03-16 The Scripps Research Institute Sistema de presentacion de antigenos y activacion de celulas-t.
US5576197A (en) * 1995-04-07 1996-11-19 Molecular Bio-Products Polymerase chain reaction container and methods of using the same
US5794221A (en) * 1995-07-07 1998-08-11 Egendorf; Andrew Internet billing method
ATE244300T1 (de) * 1996-01-17 2003-07-15 Imp College Innovations Ltd Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
JPH11507843A (ja) 1996-03-28 1999-07-13 ザ・ジョンズ・ホプキンス・ユニバーシティー タンパク質の可溶性二価および多価ヘテロ二量体類縁体
WO1997046256A1 (en) 1996-05-23 1997-12-11 The Scripps Research Institute Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
ES2277358T3 (es) 1996-09-06 2007-07-01 Ortho-Mcneil Pharmaceutical, Inc. Purificacion de celulas t especificas de antigeno.
US20020151690A1 (en) * 1997-08-12 2002-10-17 Luxemburg Alain T Purification of antigen-specific t cells
US7556805B2 (en) * 1996-12-10 2009-07-07 Sloan-Kettering Inststute for Cancer Research and The Animal Medical Center Compositions for treatment of melanoma and method of using same
CA2272407C (en) 1996-12-10 2012-07-31 Sloan-Kettering Institute For Cancer Research Method and compositions for stimulation of an immune response to a differentiation antigen stimulated by an altered differentiation antigen
US20100068262A1 (en) * 1997-02-18 2010-03-18 Sloan-Kettering Institute For Cancer Research Method and Compositions for Stimulation of an Immune Response to PSMA using a Xenogeneic PSMA Antigen
US8021666B2 (en) * 1997-02-18 2011-09-20 Sloan-Kettering Institute For Cancer Research Method and compositions for stimulation of an immune response to CD20 using a xenogeneic CD20 antigen
US20020164318A1 (en) * 1997-02-18 2002-11-07 Houghton Alan N. Cell lines and vectors for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen
US20100068263A1 (en) * 1997-02-18 2010-03-18 Sloan-Kettering Institute For Cancer Research Method and Compositions for Stimulation of an Immune Response to TRP2 using a Xenogeneic TRP2 Antigen
US20100068216A1 (en) * 1997-02-18 2010-03-18 Sloan-Kettering Institute For Cancer Research Method and Compositions for Stimulation of an Immune Response to gp100 using a Xenogeneic gp100 Antigen
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US6713250B1 (en) 1997-08-08 2004-03-30 The Research Foundation Of State University Of New York Identification of human allergens and T-lymphocyte antigens in vitro
JP4789294B2 (ja) * 1997-08-22 2011-10-12 ソレクサ・インコーポレイテッド ローリングプライマーを用いたdna伸長および分析
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6153398A (en) * 1997-12-24 2000-11-28 The University Of Chicago Method to identify specific inhibitors of IMP dehydrogenase
CA2322969A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Methods to provoke anti-cancer immune responses
WO1999064597A1 (en) * 1998-06-10 1999-12-16 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services β2 MICROGLOBULIN FUSION PROTEINS AND HIGH AFFINITY VARIANTS
US6682741B1 (en) 1998-06-10 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services β2 microglobulin fusion proteins and high affinity variants
CA2343313A1 (en) * 1998-09-14 2000-03-23 Lars Ostergaard Pedersen A method of producing a functional immunoglobulin superfamily protein
DK1179176T3 (da) * 1999-04-16 2006-08-07 Ortho Mcneil Pharm Inc Fremgangsmåde til detektion af antigenspecifikke T-celler
NZ516237A (en) * 1999-05-25 2004-03-26 Human Genome Sciences Inc Meth1 and meth2 polynucleotides and polypeptides
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
US20030077248A1 (en) * 2001-02-20 2003-04-24 Ann Moriarty Cell therapy method for the treatment of tumors
AU2008200524B2 (en) * 2001-02-20 2012-01-12 Ortho-Mcneil Pharmaceutical, Inc. A cell therapy method for the treatment of tumors
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
JP2005516581A (ja) * 2001-05-15 2005-06-09 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 自己免疫およびアレルギー疾患を処置するための非−腫瘍抗原に特異的な細胞傷害性リンパ球を生産するためのエクス−ビボプライミング
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7745140B2 (en) * 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7638325B2 (en) * 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US9535076B2 (en) 2002-09-12 2017-01-03 The Regents Of The University Of California Methods and compositions for eliciting an amyloid-selective immune response
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
EP3363907A1 (de) 2004-05-27 2018-08-22 The Trustees of the University of Pennsylvania Neue künstliches antigen präsentierende zellen und verwendungen dafür
BRPI0720342A2 (pt) 2006-10-04 2018-09-18 Janssen Pharmaceutica N.V. preparado de células apresentadoras de antígenos artificiais e seu uso em terapias celulares.
EP2231181B1 (de) 2007-12-17 2016-02-17 Marfl AB Neuer impfstoff zur behandlung von erkrankungen durch myobacterium
US8586359B2 (en) * 2009-07-28 2013-11-19 Promising Furture, LLC Compositions and methods of preparing alloreactive cytotoxic T cells
US10857219B2 (en) 2014-03-28 2020-12-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof
EP3377650A1 (de) * 2015-11-19 2018-09-26 Susanne Wagner Signaturen zur vorhersage der krebsimmuntherapiereaktion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE147990T1 (de) * 1990-05-10 1997-02-15 Dana Farber Cancer Inst Inc Erhöhung der assoziation exogener peptide mit mhci-molekülen auf zellen des immunsystems
NO175188C (no) * 1990-06-27 1994-09-14 Sjur Olsnes Fremgangsmåte for fremstilling av et peptidkonjugat med evne til å trenge inn i cellecytosol

Also Published As

Publication number Publication date
DE69334062D1 (de) 2006-10-19
AU3728193A (en) 1993-09-13
EP1249490B1 (de) 2006-09-06
WO1993017095A1 (en) 1993-09-02
JP2006022111A (ja) 2006-01-26
EP1249490A3 (de) 2003-03-05
EP0628074A1 (de) 1994-12-14
DK0628074T3 (da) 2003-04-22
DE69334062T2 (de) 2007-03-15
PT1249490E (pt) 2007-01-31
DE69332606T2 (de) 2003-10-23
EP1249490A2 (de) 2002-10-16
JP4584794B2 (ja) 2010-11-24
US5827737A (en) 1998-10-27
ES2190432T3 (es) 2003-08-01
JP3739786B2 (ja) 2006-01-25
ATE338815T1 (de) 2006-09-15
JPH07504089A (ja) 1995-05-11
DE69332606D1 (de) 2003-02-06
DK1249490T3 (da) 2007-01-08
US5314813A (en) 1994-05-24
EP0628074B1 (de) 2003-01-02
EP0628074A4 (de) 1999-01-20
ES2272611T3 (es) 2007-05-01
US5529921A (en) 1996-06-25

Similar Documents

Publication Publication Date Title
ATE230435T1 (de) In vitro aktivierung cytotoxischer t-zellen
ZA944196B (en) Isolated peptides which form complexes with MHC molecule HLA-C-clone 10 and uses thereof
ES8308534A1 (es) Un metodo de producir un polipeptido que exhibe actividad inmunologica o biologica del interferon de leucocitos humanos.
UA84387C2 (ru) Человеческий цитокин как лиганд зальфа рецептора и его применение
EP0690915A4 (de) Für den vorläufer des für die tumorabstossung verantwortlichen antigens mage-3 kodierendes, isoliertes nukleinsäuremolekül und seine verwendung
ES2156852T3 (es) Citoquina mamifera, il-11.
DE68928641D1 (de) Menschliches IFN-beta2/IL-6, dessen Reinigung und Verwendungen
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
ES8506347A1 (es) Un metodo para producir un polipeptido de tipo il-2-".
ATE209680T1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
ATE183195T1 (de) Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren
ES2074049T3 (es) Regulador del crecimiento relacionado con plaquetas.
ATE309382T1 (de) Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse
PT1007717E (pt) Processos e composicoes para terapias do cancro,utilizando genes que codificam o interferao-beta
CA2095335A1 (en) Cell growth inhibitors
ES8600518A1 (es) Metodo in vitro para detectar un estado maligno en un paciente humano.
HK53791A (en) Po-man's photosynthesis in men's blood to cure cancer(phmdcc)
GEP19970665B (en) Processes for producing human interferon-like polypeptides
UA66753C2 (en) Immunostimulator and method for its production

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0628074

Country of ref document: EP